Advances in the somatostatin receptor-targeting imaging and peptide receptor radionuclide therapy for pheochromocytomas and paragangliomas
10.3760/cma.j.cn321828-20210412-00109
- VernacularTitle:嗜铬细胞瘤和副神经节瘤生长抑素受体显像与肽受体放射性核素治疗的应用进展
- Author:
Si XU
1
;
Yifan ZHANG
Author Information
1. 上海交通大学医学院附属瑞金医院核医学科，上海 200025
- Keywords:
Pheochromocytoma;
Paraganglioma;
Receptors, somatostatin;
Receptors, peptide;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(10):623-627
- CountryChina
- Language:Chinese
-
Abstract:
Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors leading to serious complications in the cardiovascular system. As somatostatin receptor (SSTR) is highly expressed in PPGL, SSTR-targeting imaging, particularly PET/CT based on 68Ga-labelled somatostatin analog represented by 68Ga-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid- D-Phe1-Tyr3-Thr8-octreotide (DOTATATE), becomes an important tool for location and assessment of systemic metastases. Treatments for metastatic PPGL are limited. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE provides a new therapeutic option for patients with inoperable PPGL and demonstrates satisfying efficacy. This article summarizes the advances of SSTR-targeting imaging and PRRT in the diagnosis and treatment of PPGL.
